The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine-Reference-Cited by-同舟云学术

The efficacy and toxicity of the CHG priming regimen (low-dose cytarabine, homoharringtonine, and G-CSF) in higher risk MDS patients relapsed or refractory to decitabine

Published:2019-09-26 Issue:12 Volume:145 Page:3089-3097
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Xiu Cai,Li Xiao,Wu Lingyun^ORCID,Xu Feng,He Qi,Zhang Zheng,Wu Dong,Song Luxi,Su Jiying,Zhou Liyu,Zhao Youshan,Tao Ying,Chang Chunkang

Funder

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00432-019-03031-w.pdf

Reference26 articles.

1. Bejar R, Steensma DP (2014) Recent developments in myelodysplastic syndromes. Blood 124:2793–2803

2. Bennett JM, Catovsky D, Daniel MT (1976) Proposals for the classification of the acute leukaemias: French-American-British Cooperative Group. Br J Haematol 33:451–458

3. Brunning R, Orazi A, Germing U et al (2008) Myelodysplastic syndromes. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. IARC Press, Lyon, pp 87–104

4. Cheson BD, Greenberg PL, Bennett JM et al (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419–425

5. Craddock C, Quek L, Goardon N et al (2013) Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia 27:1028–1036

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes;Seminars in Hematology;2024-08

2. The effect of decitabine-combined minimally myelosuppressive regimen bridged allo-HSCT on the outcomes of pediatric MDS from 10 years’ experience of a single center;BMC Pediatrics;2022-05-27

3. Cytarabine/granulocyte colony stimulating factors/omacetaxine mepesuccinate;Reactions Weekly;2019-12